Cargando…

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors

OBJECTIVE: Multiple myeloma patients who are relapsed or refractory to both proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) have been reported to have poor outcomes. Bendamustine has been reported to have an antitumor effect in newly diagnosed as well as relapsed/refractory multiple m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yalnız, Fevzi Fırat, Akkoç, Nihan, Salihoğlu, Ayşe, Ar, M. Cem, Öngören, Şeniz, Eşkazan, A. Emre, Soysal, Teoman, Aydın, Yıldız
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544042/ https://www.ncbi.nlm.nih.gov/pubmed/28270368 http://dx.doi.org/10.4274/tjh.2016.0397

Ejemplares similares

Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options
por: Çetin, Güven, et al.
Publicado: (2014)

Retrospective Evaluation of Hairy Cell Leukemia Patients Treated with Three Different First-Line Treatment Modalities in the Last Two Decades: A Single-Center Experience
por: Öngören, Şeniz, et al.
Publicado: (2017)

Vincristine as an Adjunct to Therapeutic Plasma Exchange for Thrombotic Thrombocytopenic Purpura: A Single-Institution Experience
por: Öngören, Seniz, et al.
Publicado: (2018)

Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literature
por: Cirakoglu, Ayse, et al.
Publicado: (2022)

The prognostic value of serum levels of a proliferation-inducing ligand (APRIL) in treatment-naïve patients with chronic lymphocytic leukemia
por: ESATOĞLU, Sinem Nihal, et al.
Publicado: (2021)

Detailed Analysis of Diffuse Large B Cell Lymphoma Patients: A Single-Center, Retrospective Study
por: Ozbalak, Murat, et al.
Publicado: (2013)

Treatment Responses, Toxicity, and Survival in Patients with Classical Hodgkin Lymphoma Aged ≥50 Years: A Single-Center Experience Over Two Decades
por: Çokgezer, Simay, et al.
Publicado: (2022)

Synchronous Detection of Hairy Cell Leukemia and HIV-Negative Kaposi's Sarcoma of the Lymph Node: A Diagnostic Challenge and a Rare Coincidence
por: Aydin, Seniz Ongoren, et al.
Publicado: (2011)

Breast schwannoma in a patient with diffuse large B-cell lymphoma: a case report
por: Salihoglu, Ayse, et al.
Publicado: (2012)

466 Skin lesions in febrile neutropenic patients
por: Yemisen, Mucahit, et al.
Publicado: (2014)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
por: Arı, M. Cem, et al.
Publicado: (2012)

Secondary Infections in Febrile Neutropenia in Hematological Malignancies: More Than Another Febrile Neutropenic Episode
por: Demirel, Aslıhan, et al.
Publicado: (2015)

The Changing Epidemiology of Bloodstream Infections and Resistance in Hematopoietic Stem Cell Transplantation Recipients
por: Yemişen, Mücahit, et al.
Publicado: (2016)

Interstitial Pneumonitis in a Patient with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Recurrent Monosomies Confirmed by Interphase FISH in Three Chronic Myeloid Leukemia Cases
por: Tarkan Argüden, Yelda, et al.
Publicado: (2015)

The Impact of the COVID-19 Pandemic on the Diagnosis and Management of Patients with Classical Hodgkin Lymphoma: A Single-Center Experience
por: Kucukyurt, Selin, et al.
Publicado: (2021)

Diagnosis and Management of Classical Hodgkin Lymphoma During the COVID-19 Pandemic()
por: Küçükyurt, Selin, et al.
Publicado: (2022)

Dasatinib May Override F317L BCR-ABL Kinase Domain Mutation in Patients with Chronic Myeloid Leukemia
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Primary Gastrointestinal Diffuse Large B Cell Lymphoma Presenting with Cold Agglutinin Disease
por: Eskazan, Ahmet Emre, et al.
Publicado: (2011)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
por: Yilmaz, Umut, et al.
Publicado: (2021)

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
por: Bektaş, M., et al.
Publicado: (2022)

Short-Term Clinical Outcomes of Packed Red Blood Cell Transfusions with Isolated Enzyme-Phase Crossmatch Incompatibility: A Single-Center Cross-Sectional Study
por: Yılmaz, Umut, et al.
Publicado: (2023)

Immunomodulatory Effects of Bendamustine in Hematopoietic Cell Transplantation
por: Stokes, Jessica, et al.
Publicado: (2021)

Early Changes of Mannose-Binding Lectin, H-Ficolin, and Procalcitonin in Patients with Febrile Neutropenia: A Prospective Observational Study
por: Işlak Mutcal, Sibel, et al.
Publicado: (2016)

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients
por: Şahin, Fahri, et al.
Publicado: (2013)

Simultaneous Detection of B-Cell Chronic Lymphocytic Leukemia and Colon Adenocarcinoma in the Same Mesenteric Lymph Node
por: Eşkazan, Ahmet Emre, et al.
Publicado: (2013)

Bendamustine in patients with relapsed or refractory multiple myeloma
por: Michael, M, et al.
Publicado: (2010)

Novel Agents for the Treatment of Multiple Myeloma: Proteasome Inhibitors and Immunomodulatory Agents
por: Kurtin, Sandra E., et al.
Publicado: (2013)

Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
por: Sivaraj, Dharshan, et al.
Publicado: (2018)

Immunomodulatory Effect of Proteasome Inhibitors via the Induction of Immunogenic Cell Death in Myeloma Cells
por: Matsushita, Maiko, et al.
Publicado: (2023)

Pulmonary Radiological Findings in Patients with Acute Myeloid Leukemia and Their Relationship to Chemotherapy and Prognosis: A Single-Center Retrospective Study
por: Buğdacı, Mehmet S, et al.
Publicado: (2012)

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma
por: Domenger, Antoine, et al.
Publicado: (2023)

Upregulation of SPINK2 in acute myeloid leukemia
por: Gezer, Sümbül, et al.
Publicado: (2023)

Elevación de SPINK2 en leucemia mieloide aguda
por: Gezer, Sümbül, et al.
Publicado: (2023)

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma
por: Cerchione, Claudio, et al.
Publicado: (2016)

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide
por: Cerchione, Claudio, et al.
Publicado: (2017)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

Efficacy of retreatment with immunomodulatory drugs and proteasome inhibitors following daratumumab monotherapy in relapsed and refractory multiple myeloma patients
por: Oostvogels, Rimke, et al.
Publicado: (2018)

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial
por: Ramasamy, Karthik, et al.
Publicado: (2022)

Phase I/II trial of bendamustine, ixazomib, and dexamethasone in relapsed/refractory multiple myeloma
por: Dhakal, Binod, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jbc4nglaknan7631mom9r4bpfg